Tirzepatide is best known as a weight-loss drug, sold as Zepbound and Mounjaro. But the clinical trials behind it have looked at much more than the number on the scale.
Over the past five years, studies have tested it in type 2 diabetes, sleep apnea, fatty liver disease and heart failure. Here is what that research shows, and why its two-hormone design matters.
How Tirzepatide Works
Tirzepatide is a single peptide molecule that activates two hormone receptors. That is why researchers call it a “dual agonist.”
The first target is GLP-1, short for glucagon-like peptide-1. GLP-1 is a gut hormone that boosts insulin release after meals, slows stomach emptying and reduces appetite.
The second target is GIP, short for glucose-dependent insulinotropic polypeptide. GIP also helps the body release insulin after eating, and it plays a role in how fat tissue stores energy.
Earlier drugs such as semaglutide act on GLP-1 only, and diet still matters with any of them, as this guide on what to eat on semaglutide explains. Adding GIP was tirzepatide’s main design change, and the trials below tested whether it made a difference.
Approved Medicine and Research Compound
In the United States, the FDA approved tirzepatide as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023. In Europe, it is sold as Mounjaro for both uses.
Because the molecule is so widely studied, tirzepatide is also produced as a research reagent for laboratory and preclinical work. Suppliers such as Celvive Peptides list it for laboratory research only, not for human or veterinary use.
That research-grade material is a different category from the licensed medicine. Anyone considering tirzepatide as a treatment should speak with a doctor who can prescribe the approved product.
Type 2 Diabetes: The First Test
Tirzepatide’s development began in diabetes. The SURPASS trial program compared it with placebo and with existing diabetes drugs.
In SURPASS-2, published in the New England Journal of Medicine in 2021, tirzepatide lowered HbA1c more than semaglutide over 40 weeks. HbA1c is a blood test that reflects average blood sugar over about three months.
Participants on tirzepatide also lost more body weight than those on semaglutide, which pointed researchers toward obesity trials.
Obesity: The SURMOUNT Trials
SURMOUNT-1, published in the New England Journal of Medicine in 2022, enrolled adults with obesity or overweight who did not have diabetes.
Over 72 weeks, average weight loss reached about 21% in the highest-dose group, compared with about 3% on placebo. Those results led to the Zepbound approval for weight management.
Beyond Weight: Newer Trial Results
The more recent trials asked whether those metabolic effects improve specific conditions linked to obesity.
Obstructive Sleep Apnea
Obstructive sleep apnea causes repeated breathing pauses during sleep. In the SURMOUNT-OSA trials, published in 2024, tirzepatide reduced the number of breathing interruptions per hour compared with placebo.
Based on these results, the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity in December 2024.
Fatty Liver Disease
MASH, or metabolic dysfunction-associated steatohepatitis, is an advanced form of fatty liver disease with inflammation and liver cell damage.
In the phase 2 SYNERGY-NASH trial, published in 2024, more participants on tirzepatide saw their MASH resolve without fibrosis getting worse, compared with placebo. Fibrosis is the scarring that can lead to cirrhosis.
Heart Failure
The SUMMIT trial, published in the New England Journal of Medicine in 2025, studied adults with obesity and heart failure with preserved ejection fraction (HFpEF). In HFpEF, the heart pumps normally but is too stiff to fill properly.
Tirzepatide lowered the combined risk of cardiovascular death or worsening heart failure compared with placebo. Participants also reported better symptoms and physical limitations.
GIP Debate
Tirzepatide’s results raised an interesting question for researchers: is activating GIP the right approach?
Some newer compounds in development do the opposite. They combine GLP-1 activation with GIP blocking, and early trials of that approach also produced substantial weight loss.
Both strategies appear to work, which suggests the biology of GIP in fat tissue and the brain is more complex than first thought. This is one of the most active areas in metabolic research today.
What This Means for Patients
Tirzepatide’s research record now extends well beyond weight loss. Approved uses cover type 2 diabetes, chronic weight management and obstructive sleep apnea in adults with obesity.
Common side effects are gastrointestinal, including nausea, diarrhea and constipation, especially when the dose is increased. It is not right for everyone, and the decision belongs with a qualified clinician.
For anyone following metabolic health research, tirzepatide is also a useful reference point. Newer compounds, including triple-receptor agonists, are measured against the results it set.
Disclaimer: This article is for general information only and is not medical advice. Research findings do not guarantee individual results. Tirzepatide is a prescription medicine and should only be used under qualified medical supervision. Research-grade products are not approved for human use. Consult a healthcare professional about potential benefits, risks and suitability.